Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0914 MFN order
BioCentury & Getty Images

Politics, Policy & Law

PhRMA rejects Trump election gambit, triggering most favored nation order

Most favored nation order faces legal, logistic challenges

Most favored nation order faces legal, logistic challenges.

Sep 14, 2020 | 5:40 PM GMT

Seeking to avoid the perception that it was intervening in the U.S. presidential election, PhRMA’s board last week rejected a proposal from the Trump administration to include Medicare Part D gift cards in a drug pricing deal. The rejection torpedoed a deal the industry had negotiated with the White House, triggering President Donald Trump’s decision to issue a “most favored nation” drug pricing executive order.

The PhRMA board had approved a deal that would

Read the full 1124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers